David Nierengarten

David Nierengarten

Analyst-Equity presso
Wedbush Securities, Inc.
Finance
Consumer Services
Health Technology

Profilo

Dr. David Nierengarten is a Senior Analyst at Wedbush Securities, Inc. Dr. David Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy.
His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models.
In addition, Dr. David Nierengarten, Ph.D.
has results in predicting Dendreon's looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor.
Dr. David Nierengarten, Ph.D.
received his B.S.
in Biochemistry from the University of Wisconsin-Madison, and Ph.D.
in Molecular and Cell Biology from the University of California at Berkeley.

Posizioni attive di David Nierengarten

SocietàPosizioneInizio
Analyst-Equity -

Precedenti posizioni note di David Nierengarten

SocietàPosizioneFine
Corporate Officer/Principal 30/11/2010
Analyst-Equity 30/06/2007
Corporate Officer/Principal 30/05/2007
Corporate Officer/Principal 31/12/2004
Vedi nel dettaglio l'esperienza di David Nierengarten

Formazione di David Nierengarten

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

100 +

Relazioni di 1° grado

7

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private7

Finance

Health Technology

Finance

Consumer Services

Consumer Services

Finance

Finance

  1. Mercati
  2. Insiders
  3. David Nierengarten